Associate Director, Pricing Analytics

Who We Are Cogent Biosciences is a publicly traded biotechnology company dedicated to developing precision therapies for genetically defined diseases. By leveraging validated biology and a rational drug discovery approach, Cogent aims to create real solutions that address the underlying drivers of disease and offer meaningful hope to patients. The company’s lead therapeutic candidate, Bezuclastinib, is a highly selective tyrosine kinase inhibitor designed to potently target KIT D816V and other mutations in KIT exon 17. These mutations are known drivers of systemic mastocytosis (SM) and advanced gastrointestinal stromal tumors (GIST) – both serious conditions driven by oncogenic KIT signaling. Bezuclastinib is currently being evaluated in multiple registration‑directed trials across Non‑Advanced SM (NonAdvSM), Advanced SM (AdvSM), and GIST. In July 2025, Cogent announced that its registration‑direct SUMMIT trial in patients with NonAdvSM achieved statistical significance across all primary and key secondary endpoints, and the company is on track to file its first New Drug Application for this patient population by the end of 2025. The company also remains on track to announce top‑line results for its APEX trial in patients with AdvSM in the second half of 2025 and for its PEAK trial in patients with GIST by the end of 2025. The company also has an ongoing Phase 1 study of its novel internally discovered FGFR2 inhibitor, and the Cogent Research Team is developing a portfolio of novel targeted therapies to help patients fighting other serious, genetically driven diseases targeting mutations in ErbB2, PI3Kα and KRAS. Through its commitment to precision medicine and targeted innovation, Cogent Biosciences is working to transform the treatment landscape for patients with serious and underserved diseases. By leveraging validated biology and a rational drug discovery approach, Cogent aims to create real solutions that address the underlying drivers of disease. Our culture of inquisitiveness fuels continuous learning and innovation; we challenge assumptions, ask bold questions, and embrace a mindset of discovery to uncover transformative insights. The Role The Associate Director, Pricing Analytics will lead the development of U.S.‑focused pricing models and analytics to inform strategic decisions around launch pricing, payer negotiations, and value‑based arrangements. This role will collaborate closely with Market Access Strategy, Finance, and Commercial teams to support data‑driven pricing strategy that ensures both commercial success and broad patient access. This position will be based in Waltham, Massachusetts. Key Responsibilities Develop and maintain models to support optimal pricing and contracting decisions for bezuclastinib. Develop tools to track contract performance and recommend contract updates, as needed. Partner with cross‑functional teams to support business cases, launch planning, GTN, and strategic planning processes. Create dashboards, presentations, and tools to communicate pricing insights to internal stakeholders. Support the Director of Pricing Strategy in the regular verification of Government Price reporting. Analyze the impact of U.S. healthcare policy changes, such as the Inflation Reduction Act (IRA) and drug pricing reforms. Qualifications 6+ years of pharmaceutical or biotech experience in market access, pricing, analytics, and/or relevant commercial roles. Strong business acumen and ability to distill complex data into clear insights and recommendations. Proficiency in data analysis and modeling. Deep understanding of the access landscape for pharmaceutical benefit products. Preferred Skills New product launch and/or start‑up experience. Prior experience in targeted therapies and/or oncology. Strong financial management and business acumen. Experience formulating U.S. pricing policy and contracting analyses and business cases. Salary Range $175,000 - 205,000 USDTarget Bonus: 20%Exact compensation will vary based on skills, experience, and locations Our Locations Waltham, MA: Our Boston office includes an open office layout that has recently undergone a makeover designed for collaboration and giving our employees the best workplace possible. Free access is provided for both on‑site parking and gym facilities in the building. Boulder, CO: Our Boulder office includes state‑of‑the‑art Research Facility in the fast‑growing biopharmaceutical hub in the greater Denver/Boulder corridor. Our CEO is based full‑time in this location and we are proud to call this the home of Cogent’s discovery research organization. Our Offer To You To attract the very best talent, we offer a generous benefits package that includes competitive pay, performance‑based bonus, stock options, insurance coverage (health, dental, life, and disability), competitive time‑off, a 401(k) plan, and commuter/parking benefits. We are proud to be an Equal Opportunity Employer. Our goal is to have a diverse workforce. We do not discriminate on the basis of race, age, color, religion, national origin, gender, sexual orientation, gender identity or expression, veteran status or disability, or any other status protected under federal, state, or local law. All employment is decided on the basis of qualifications, merit, and business need. #J-18808-Ljbffr